FDA Inspection 1320962 — Rosemont Pharmaceuticals Ltd.
The FDA completed an inspection of Rosemont Pharmaceuticals Ltd. on Apr 24, 2026 in Leeds. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 24, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Leeds (United Kingdom)